Bausch Health’s (BHC) Canadian Subsidiary Lists PrOKEDI Dosages in RAMQ Formulary

July 12, 2026 - 19:23

Bausch Health Companies Inc., a company that has drawn attention from hedge funds as one of the more closely watched penny stocks on the New York Stock Exchange, announced a regulatory win for its Canadian division. On July 6, Bausch Health Canada confirmed that two specific dosages of its product PrOKEDI have been added to the formulary of the Regie de l'assurance maladie du Quebec, commonly known as RAMQ.

The listing covers the 75mg and 100mg injectable versions of PrOKEDI. Being included in the RAMQ formulary means that eligible patients in Quebec can now receive coverage for these dosages through the provincial public drug insurance plan. This is a significant step for market access in Canada's second-most populous province, as formulary listing often directly impacts prescribing habits and patient affordability.

PrOKEDI is an injectable medication, and the expansion of its covered dosages could broaden the treatment options available to physicians in Quebec. For Bausch Health, which has been navigating a complex corporate structure and debt reduction efforts, this listing provides a tangible milestone for its Canadian operations. The company continues to focus on its core pharmaceutical portfolio while managing its status as a lower-priced stock that some institutional investors have targeted for potential value.